Which patients is suitable for upadatinib?

Upadacitinib, as a highly efficient and selective JAK1 inhibitor, is gradually emerging in the treatment of various immune-mediated diseases. So, which patients are suitable for upatinib? The following will explain it in detail for you.

Upadatinib is undoubtedly a new treatment option for adult patients with rheumatoid arthritis, especially those who have poor response or intolerance to traditional antirheumatic drugs (DMARDs). Rheumatoid arthritis, a chronic autoimmune disease, often causes joint pain, swelling and dysfunction, seriously affecting patients' quality of life. Upadatinib can effectively relieve joint symptoms by accurately inhibiting the inflammatory response, allowing patients to regain relaxation and freedom.

Upadatinib also brings hope to patients with moderate to severe atopic dermatitis. Atopic dermatitis, a chronic skin disease characterized by dryness, itching and skin inflammation, brings endless trouble to patients. For those patients who have poor local treatment results or poor response to systemic treatments, upadatinib can significantly reduce skin inflammation and itching by regulating the immune system response, improve the overall health of the skin, and help patients regain confidence and comfort.

In addition, upadatinib is approved for the treatment of patients with moderate to severe ulcerative colitis. Ulcerative colitis, a chronic disease that affects the intestines, often causes abdominal pain, diarrhea and other gastrointestinal symptoms, seriously affecting patients' daily lives. For those patients who are ineffective or intolerant to other treatments (such as biologics or traditional immunosuppressants), upadatinib brings new treatment hope to patients by inhibiting inflammation and promoting mucosal healing, helping them regain health and vitality.

In addition to the above main indications, researchers are also actively exploring the potential application of upadatinib in other autoimmune diseases. For example, research on immune-mediated diseases such as vitiligo and Sjögren's syndrome is in full swing, and it is expected to further expand the applicable population of upadatinib and bring good news to more patients.